JERUSALEM, Nov. 19, 2018 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage
biopharmaceutical company focused on developing and commercializing
M-001, a universal flu vaccine candidate, today issued a
clarification regarding information published on November 13, 2018 in connection with the third
quarter financial results.
As correctly indicated in the financial tables filed on
November 14, 2018 in a 6-K with the
United States Securities And Exchange Commission (SEC), third
quarter operating expenses were NIS
5.8m (US$1.6m), while
cumulative operating expenses for the nine months ending
September 30, 2018 were NIS 49.1m (US$13.5m). As well, third quarter R&D
expenses amounted to NIS 4.3m
(US$1.2m), while cumulative
R&D expenses for the nine months ending September 30, 2018 were NIS 45.3m (US$12.5m).
Note that results are in New Israel Shekels (NIS) and the
convenience translation to $US is provided using the exchange rate
of 3.627 (NIS/$US) as at September 30,
2018.
About BiondVax
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage
biopharmaceutical company developing a universal flu vaccine. The
vaccine candidate, called M-001, is designed to provide
multi-season protection against current and future, seasonal and
pandemic influenza virus strains. BiondVax's proprietary technology
utilizes a unique combination of conserved and common influenza
virus peptides, activating both arms of the immune system for a
cross-protecting and long-lasting effect. In a total of 6 completed
Phase 1/2 and Phase 2 human clinical trials, covering 698
participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. Please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements involve certain risks and uncertainties reflect the
management's current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals Ltd.
Risks and uncertainties include, but are not limited to, the
prosecution and outcome of the ongoing Phase 2 and Phase 3 trials
and any subsequent trials; timing of receipt of regulatory
approval of the new manufacturing facility its products; ability to
demonstrate the efficacy and safety of the vaccine; the timing of
clinical trials and marketing approvals; the risk that drug
development involves a lengthy and expensive process with uncertain
outcome; the ability of the Company to maintain, preserve and
defend its intellectual property and patents granted; whether
our vaccine candidate will successfully advance through the
clinical trial process on a timely basis, or at all, and receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; the
adequacy of available cash resources and the ability to raise
capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2017 filed
with the U.S. Securities and Exchange Commission, or SEC, which is
available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC. We undertake no obligation
to revise or update any forward-looking statement for any
reason.
Contact Details: Joshua
E.Phillipson,
+972-8-930-2529, j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/biondvax-issues-clarification-regarding-third-quarter-2018-financial-results-300752751.html
SOURCE BiondVax Pharmaceuticals Ltd.